# OnCo record necitumumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/necitumumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "necitumumab" ;
  schema:name "Necitumumab"@en ;
  schema:description "Necitumumab (Portrazza) is an antibody added to gemcitabine and cisplatin as first treatment for squamous non-small cell lung cancer that has spread; the benefit is modest and it is little used."@en ;
  schema:url <https://onco.cc/drugs/necitumumab/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Necitumumab> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=necitumumab>, <https://www.cancer.gov/about-cancer/treatment/drugs/necitumumab>, <https://www.ema.europa.eu/en/medicines/human/EPAR/portrazza> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Monoclonal antibody (anti-EGFR, IgG1)" ;
  schema:alternateName "Portrazza" ;
  onco:approval "US 2015: First-line metastatic squamous NSCLC with gemcitabine and cisplatin", "EU 2016: EGFR-expressing locally advanced or metastatic squamous NSCLC with gemcitabine and cisplatin" ;
  onco:related <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:trials <https://onco.cc/trials/nct03944772/> .